Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License ...
Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback